Fibroblast Growth Factor 23 in Chronic Respiratory Failure

Status Not yet recruiting

Clinical Trial Summary

Fibroblast growth factor 23 (FGF23) is a key hormone of the mineral metabolism produced in bone and acting on the kidney to lower phosphatemia. FGF23 is subject to inactivating proteolytic cleavage which results in the presence of C-terminal and N-terminal fragments heretofore described as inactive. We recently showed an increase in FGF23Ct in sickle cell patients, its association with left ventricular mass as well as a direct, pro-hypertrophic effect of FGF23Ct on rat cardiomyocytes. Data from the literature suggest that hypoxia (linked or not to anemia) is responsible for an increase in the production and cleavage of FGF23, either via the hypoxia inducible factor (HIF1α) or via the increase in erythropoietin (EPO). We hypothesize that the FGF23Ct / FGF23i ratio is increased in response to chronic tissue hypoxia, in the absence of anemia, in patients with chronic respiratory failure (CRF) either due to a direct response to hypoxia via the stimulation of HIF1α, or indirectly via the increase in the circulating concentration of EPO. This elevation, if proven, could contribute to the increased risk of heart disease seen in some populations of CRF. We propose to test this hypothesis by assaying FGF23Ct and FGF23i in a cohort of adult CRF patients before and after initiation of oxygen therapy. The object of the present study is to study the FGF23Ct / FGF23i ratio in incident patients presenting with a non treated CRF as well as the modifications of this ratio under oxygen therapy and to study the correlations between FGF23 Ct and FGF23 and i) oxygen saturation and PaO2 ii) echocardiographic parameters and iii) EPO concentrations. Three visits are planned: Baseline (before initiation of oxygen therapy), and two visits after initiation of oxygen therapy, at 3 months (M3) and at 12 months (M12). For each visit, anthropometric and clinical data, treatment and biological results will be collected. FGF23 intact , FGF23 C-terminal and Erythropoietin will be measured. A cardiac ultrasound will be performed at baseline and at M12.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05258370
Study type	Observational
Source	Assistance Publique - Hôpitaux de Paris
Contact	Natacha Nohilé
Phone	331 56 09 59 82
Email	natacha.nohile@aphp.fr
Status	Not yet recruiting
Phase
Start date	June 2023
Completion date	May 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05084976` - Parental Perception of COVID-19 Vaccine in Technology Dependent Patients
Enrolling by invitation	`NCT04208581` - Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure	Phase 3
Recruiting	`NCT02260583` - Effect of Extracorporeal CO2 Removal in Stable Hypercapnic COPD Patients	N/A
Completed	`NCT01255111` - Adaptation to Nocturnal Noninvasive Ventilation in Patients With Chronic Respiratory Failure (ROOMILA)	N/A
Active, not recruiting	`NCT03499470` - Structured Discharge and Follow-up Protocol for COPD Patients Receiving LTOT and NIV	N/A
Completed	`NCT04143230` - Identification of In-hospital Patients in Need of Palliative Care Using a New Simplified Screening Tool	N/A
Terminated	`NCT00208078` - Effect of Non-Invasive Ventilation in Cystic Fibrosis Patient With Chronic Respiratory Failure.	Phase 4
Recruiting	`NCT06286917` - Initiation of Noninvasive Ventilation in ALS Patients With Chronic Respiratory Insufficiency	N/A
Not yet recruiting	`NCT05756387` - Improving Chronic Nocturnal Noninvasive Ventilation: a Multimodality Approach
Completed	`NCT02342899` - Cost Effectiveness of Outpatient Set-up of Automated NIV in Obese Patients With Chronic Respiratory Failure	Phase 3
Terminated	`NCT03473171` - Implementation of Nasal Non-Invasive Ventilation With a RAM Cannula in the Inpatient /Outpatient Setting	N/A
Completed	`NCT02804243` - The Efficacy of Nasal High Flow Oxygen Therapy With Rehabilitation in the Patients With Chronic Respiratory Failure	N/A
Completed	`NCT01479959` - Impact of Patient Controlled Positive End-expiratory Pressure on Speech in Tracheostomized Ventilated Patients	N/A
Completed	`NCT01090986` - Home Mechanical Ventilation Effectiveness and Air Leaks	N/A
Completed	`NCT00698958` - Ambulatory Adaptation to Non-Invasive Mechanical Ventilation	Phase 4
Not yet recruiting	`NCT06119087` - Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study	N/A
Recruiting	`NCT05796297` - Clinical Impact of Patient-ventilator Asynchrony
Recruiting	`NCT04481295` - Study on Optimal Oxygen Concentration During Pulmonary Rehabilitation	N/A
Withdrawn	`NCT05379439` - Family Connections	N/A
Terminated	`NCT03809832` - Microbiologic Contamination of Home Non Invasive Ventilators

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Fibroblast Growth Factor 23 in Chronic Respiratory Failure — EFIC-RES

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms